Maccecchini Maria-Luisa was granted 40,970 shares, increasing direct ownership by 4% to 1,098,459 units (SEC Form 4) (Amendment)

$ANVS
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ANVS alert in real time by email
SEC FORM 4/A SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Maccecchini Maria-Luisa

(Last) (First) (Middle)
C/O ANNOVIS BIO, INC.
1055 WESTLAKES DRIVE, SUITE 300

(Street)
BERWYN PA 19312

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Annovis Bio, Inc. [ ANVS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
11/20/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
11/21/2023
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/20/2023 A 40,970 A $6.1 1,098,459 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
This amendment is being filed solely to reflect the modification of the terms of the previously reported purchase on the original form 4 filed on November 21, 2023 (the "Original Form 4"), as agreed to by the registrant and the reporting person on November 22, 2023.
/s/ Henrey Hagopian III, Attorney-in-Fact for Maria L. Maccecchini 11/22/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ANVS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ANVS

DatePrice TargetRatingAnalyst
2/10/2025Buy → Hold
D. Boral Capital
10/25/2024$25.00Hold → Buy
Maxim Group
12/29/2023$36.00Buy
Canaccord Genuity
7/7/2021$45.00 → $150.00Buy
Maxim Group
More analyst ratings

$ANVS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

    MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), will participate at the 13th Alzheimer's & Parkinson's Drug Development Summit happening on March 18-20 in Boston, MA. "This meeting represents an important opportunity to advance our understanding of the next-generation treatment for neurodegenerative diseases, which we have long argued are too complex for a narrow therapeutic approach. Research must shift to a more holistic solution, addressing multiple neurotoxic proteins and

    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Annovis to Host Patients' Live Forum on February 27, 2025

    MALVERN, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE:ANVS)  ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), will host a live webcast where CEO Maria Maccecchini, Ph.D., will answer questions from patients, caregivers, and families about the Company's clinical trials and future plans. Webcast Details Event: Annovis Patients' Forum: Your Questions AnsweredDate: February 27, 2025Time: 4:30 PM ESTRegistration: Click here to register During the webcast, Dr. Maccecchini will provide updates on the on

    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

    MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that its CEO, Maria Maccecchini, Ph.D., will present at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference. Presentation details Date: February 11, 2025Time: 12:40 – 1:10 p.m. ET Attendees can access the live presentation through the conference's virtual platform. Dr. Maccecchini will discuss the Company's latest advancements, highlighting the progress of the

    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANVS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ANVS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ANVS
SEC Filings

See more

$ANVS
Leadership Updates

Live Leadership Updates

See more
  • Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

    MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis' clinical trials. "We are thrilled to welcome Matthew Peterson to our team," said Cheng Fang, Ph.D., Senior Vice President, Research and Development,

    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Annovis Bio Appoints Andrew Walsh as Vice President Finance

    BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) today announced the appointment of Andrew Walsh as VP, Finance.  "We remain steadfast in advancing our lead candidate buntanetap, as we gear up to receive pivotal data from both our Alzheimer's and Parkinson's clinical trials in 2024. The addition of Andrew Walsh to our team marks another step in our growth plans," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Andrew brings 12 years of extensive experience in finance operations, adding a

    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • TheracosBio Announces the Appointments of Jim Greenwood to Board of Directors and Jeff McGroarty as Chief Financial Officer

    TheracosBio today announced the appointment of former US Congressman Jim Greenwood to the Board of Directors of its parent company and Jeff McGroarty, MBA, as its Chief Financial Officer. Congressman Greenwood is an established leader in life sciences across business and public policy, and Mr. McGroarty has served as a CFO of public and private life sciences and technology companies. Both newly appointed team members will help shape the commercial strategy for Brenzavvy™ (bexagliflozin), a recently FDA-approved treatment for type 2 diabetes. "Accomplished leaders, Jim and Jeff will be valuable members of our team at this critical time for TheracosBio," said Albert R. Collinson, Ph.D., Pres

    $ANVS
    $SFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance/Investors Services
    Finance

$ANVS
Financials

Live finance-specific insights

See more
  • Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson's Disease

    Data Shows Statistically Significant Improvements in Speed and Motor Function in PD PatientsAnnovis Bio to Request Meeting with FDA on Next Steps in Clinical DevelopmentInvestor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ETBerwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor funct

    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANVS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more